Tanja Fauti

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models

Sylvia Herter, Frank Herting, Olaf Mundigl et al. · Molecular Cancer Therapeutics · 2013 · 359 citations

Pharmacy, Cell Biology, Immunology +17

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

Marina Bacac, Tanja Fauti, Johannes Sam et al. · Clinical Cancer Research · 2016 · 355 citations · Full text

Pharmacy, Immunology, Oncology +17

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

Anja Seckinger, Jose Antonio Delgado, Samuel Moser et al. · Cancer Cell · 2017 · 312 citations · Full text

Medicine, Oncology, Pharmacology +17

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Christina Claus, Claudia Ferrara, Wei Xu et al. · Science Translational Medicine · 2019 · 266 citations · Full text

Medicine, Immunology, Oncology +17

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo‐Stella, Rita Mazza, Salomon Manier et al. · Blood · 2022 · 90 citations

Medicine, Oncology, Pharmacotherapy +17